SCHEMBL23979410

SCHEMBL23979410

BC1(B)CC[C@@](B)(N2Cc3c(N)cccc3C2=O)C(=O)NC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 2/20 0.41
▸ IL1B P01584 2/20 0.41
▸ IKZF1 Q13422 2/20 0.41
▸ DDB1 Q16531 2/20 0.41
▸ CRBN Q96SW2 2/20 0.41
▸ IKZF3 Q9UKT9 2/20 0.41
▸ BRD4 O60885 1/20 0.41
▸ PARP1 P09874 1/20 0.34
▸ TBXA2R P21731 1/20 0.33
▸ PTPRC P08575 1/20 0.32
▸ ADORA2A P29274 1/20 0.32
▸ UGCG Q16739 1/20 0.32
▸ HSPA1A P0DMV8 1/20 0.31
▸ PABPC1 P11940 1/20 0.31
▸ HTR3E A5X5Y0 1/20 0.30
▸ HTR3B O95264 1/20 0.30
▸ HTR2B P41595 1/20 0.30
▸ HTR3A P46098 1/20 0.30
▸ TMEM97 Q5BJF2 1/20 0.30
▸ HTR3D Q70Z44 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23979466 1.00 TNF (0.41) TNFIL1BIKZF1DDB1CRBN
SCHEMBL23979354 1.00 TNF (0.41) TNFIL1BIKZF1DDB1CRBN
SCHEMBL23979453 0.83 CRBN (0.47) TNFIL1BIKZF1DDB1CRBN
SCHEMBL23979978 0.83 CRBN (0.47) TNFIL1BIKZF1DDB1CRBN
SCHEMBL23979565 0.83 CRBN (0.47) TNFIL1BIKZF1DDB1CRBN
SCHEMBL23979895 0.81 DDB1 (0.40) TNFIL1BIKZF1DDB1CRBN
SCHEMBL23979365 0.81 DDB1 (0.40) TNFIL1BIKZF1DDB1CRBN
SCHEMBL23979387 0.81 DDB1 (0.40) TNFIL1BIKZF1DDB1CRBN
SCHEMBL18826107 0.76 TNF (0.42) TNFIL1BIKZF1DDB1CRBN
SCHEMBL23979456 0.71 CASP3 (0.37) DDB1CRBNIKZF3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same SALARIUS PHARMACEUTICALS, INC. (US) 2023-10-03 — — US disclosed
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME SALARIUS PHARMACEUTICALS, INC. 2021-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same HPGDS, HPGD, AQP3 TNF 2820/4885IL1B 3213/4885IKZF1 429/4885
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME HPGDS, HPGD, AQP3 TNF 2820/4885IL1B 3213/4885IKZF1 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback